Pass-Through Technical Corrections Act

Bill: 116-hr-5057
Sponsor: full_name: Rep. Tonko, Paul [D-NY-20]
Introduced: 2019-11-12
Policy area: Health
Subjects: Drug therapy

Home and outpatient care

Hospital care

Medicare
Latest action: action_date: 2019-11-13
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2019-11-12
action_desc: Introduced in House
text: <p><b>Pass-Through Technical Corrections Act</b></p> <p>This bill specifically extends the duration of pass-through status (i.e., additional payment) for certain radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. In particular, the bill provides that a radiopharmaceutical with an indication for certain PET imaging that is covered in relation to clinical studies (i.e., coverage with evidence development) continues to receive pass-through status until the applicable coverage review is complete, if such status initially expired on either December 31, 2017, or December 31, 2018.</p>

tv_txt: I 116th CONGRESS 1st Session H. R. 5057 IN THE HOUSE OF REPRESENTATIVES November 12, 2019 Mr. Tonko (for himself and Mr. McKinley ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To clarify the treatment of pass-through status under the Medicare outpatient payment system for certain drugs.

1. Short title This Act may be cited as the Pass-Through Technical Corrections Act . 2. Clarification of pass-through status under Medicare OPPS for certain drugs Notwithstanding section 1301 of the Consolidated Appropriations Act of 2018 ( Public Law 115–141 ), in the case of a radiopharmaceutical drug for which pass-through status was provided pursuant to section 1833(t)(6) of the Social Security Act ( 42 U.S.C. 1395l(t)(6) ) and whose period of pass-through status initially expired on either December 31, 2017, or December 31, 2018, if such radiopharmaceutical drug is indicated for positron emission tomography beta amyloid imaging covered under a coverage evidence development determination under section 1862(a)(1)(E) of the Social Security Act ( 42 U.S.C. 1395y(a)(1)(E) ), then such pass-through status shall be extended until such date that the coverage with evidence development review is determined by the Centers for Medicare & Medicaid Services to be completed.